Cytori Therapeutics De: (NASD: CYTX)

$2.51

-0.03 (-1.18%)

Volume 180,428

May 22 04:00 PM ET

Zacks Rank: 2-Buy

 
#2
 
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 2.50 - 2.60
52wk Low - High 2.04 - 4.93
Previous Close 2.54
Avg. Volume 229,350
Industry MED-BIOMED/GENE
Market Cap 170.62 M
Div - Yield 0.00 - 0.00
Beta 1.90
PE (Forward) 0.00
Current Year Est. -0.43
Quarterly Earnings ESP 0.00%

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Rank Change Trend2

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Outperform

Zacks Industry Rank

96 out of 265

Equity Research Report

Updated as of 05/13/2013

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

PE (Forward) NA
PEG Ratio NA
Current Year Est. -0.43
Current Quarter Estimate -0.13
Most Accurate Estimate -0.13
Earnings ESP 0.00%
Next Earnings Report Date 08-07-2013
EPS Last Year -0.49
Expected Earnings Growth NA

Company Description

Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

CYTX Chart by YCharts

Earnings Estimates

Current Qtr
(06/2013)
Next Qtr
(09/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate -0.13 -0.11 -0.43 -0.34
Number of Estimates 3 3 3 3
Low Estimate -0.13 -0.12 -0.47 -0.41
High Estimate -0.12 -0.10 -0.40 NA
Year Ago EPS -0.12 -0.17 -0.55 -0.43
EPS Growth -5.56% 35.29% 21.21% 22.31%

Average Earnings Estimates for CYTX

EPS Growth for CYTX

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
CYTORI THERAPEU CYTX 2.54
AETERNA ZENTARS AEZS 2.08
ANIKA THERAPEUT ANIK 14.45
GENTIUM SPA-ADR GENT 8.90
AASTROM BIOSCI ASTM 0.57
ACHILLION PHARM ACHN 7.75
ADDEX THERA LTD ADDXF 6.94
AFFYMAX INC AFFY 1.45
ALEXION PHARMA ALXN 102.67
ALKERMES INC ALKS 31.98

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.